Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AYTU vs EOLS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EOLS Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 5–5 Matrix Metrics)

EOLS Overall Winner 6-Pillar Tally: AYTU 3 – 3 EOLS Matrix Metrics: AYTU 5 – 5 EOLS

As of Nov 16, 2026, Evolus, Inc. (EOLS) is the stronger overall head-to-head candidate over AYTU BioPharma, Inc. (AYTU) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). AYTU carries a Unified Composite Score of 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin), whereas EOLS carries 47.8/100 (HOLD) at $6.69 (24.9x Forward P/E, -5.4% operating margin).

  • Composite vs. Pillar Nuance: While AYTU currently prints a higher short-term Unified Composite Score (48.9/100 HOLD vs. EOLS 47.8/100 HOLD), EOLS captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-5.4% vs. -14.4% operating margin) and revenue trajectory (+13.0% vs. +6.4% YoY).
  • Technical & Structure Timing Caution: AYTU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7); meanwhile EOLS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AYTU vs EOLS
AYTU NASDAQ
AYTU BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$1.81
+1.69% 1D
Market Cap $19.6M
TTM Revenue $58M
Forward P/E 9.2x
Beta / 30D Vol 0.65β · 35% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 49.0 Fund 53.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.8%), weak momentum, RSI 38
RSI-14: 37.7 · SMA20: $1.89 · SMA50: $2.00
EOLS NASDAQ Head-to-Head Winner
Evolus, Inc. Common Stock
Pharmaceutical Preparations
$6.69
-3.88% 1D
Market Cap $475.2M
TTM Revenue $325M
Forward P/E 24.9x
Beta / 30D Vol 1.31β · 60% Vol
Unified Composite Score
47.8 / 100 HOLD
Tech 51.0 Fund 53.0 Flow 72.0 Mom 39.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.7%), weak momentum, RSI 42
RSI-14: 42.3 · SMA20: $7.20 · SMA50: $7.57

6-Pillar Scorecard Institutional Category Breakdown (AYTU 3 – 3 EOLS)

Columns: Metric · AYTU · EOLS
1. Valuation Multiples AYTU
Forward P/E 9.2x 24.9x
Trailing P/E 9.2x 14.9x
PEG Ratio N/M N/M
EV / Revenue 0.3x 1.8x
2. Growth & Scale EOLS
Revenue Growth (YoY) +6.4% +13.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $58M $325M
Market Cap $19.6M $475.2M
3. Profitability & Quality EOLS
Gross Margin 64.0% 66.1%
Operating Margin -14.4% -5.4%
Net Profit Margin -24.8% -9.6%
Return on Equity (ROE) -52.5% -18729.6%
4. Balance Sheet & Cash Flow AYTU
Cash Generation (TTM) -$1.4M -$8.8M
Cash Flow Margin -2.4% -2.7%
Net Cash / Leverage $4.9M Net Cash $124M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EOLS
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 46.4% (4th %ile)
Put/Call OI Skew N/A 0.07x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat AYTU
OpEx & R&D Intensity 78.4% of Rev ($45M) 71.5% of Rev ($233M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AYTU (5) vs EOLS (5)
Institutional Metric AYTU EOLS Criterion Row Edge
Market Capitalization
Scale
$19.6M $475.2M Larger Scale EOLS
Trailing P/E Ratio
Valuation
9.2x 14.9x Lower Multiple AYTU
Forward P/E Ratio
Valuation
9.2x 24.9x Lower Multiple AYTU
Revenue Growth (YoY)
Growth
+6.4% +13.0% Higher Growth EOLS
Operating Margin (TTM)
Profitability
-14.4% -5.4% Higher Margin EOLS
Net Profit Margin
Profitability
-24.8% -9.6% Higher Margin EOLS
Return on Equity (ROE)
Capital Efficiency
-52.5% -18729.6% Higher ROE AYTU
52-Week Range Position
Momentum
5% ($2–$3) 52% ($4–$9) Stronger Trend EOLS
Beta / 30D Volatility
Risk Regime
0.65β · 35% Vol 1.31β · 60% Vol Lower Realized Risk AYTU
Unified Institutional Score
Composite Signal
48.9 / 100 (HOLD) 47.8 / 100 (HOLD) Higher Composite AYTU
Trailing 12M Revenue (USD)
Operating Scale
$58M $325M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
64.0% 66.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.3x EV/Rev N/M PEG · 1.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$1.4M ($4.9M Net Cash) -$8.8M ($124M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EOLS +5.5 pp
AYTU: -11.27% · EOLS: -5.77%
3M Horizon EOLS +5.09 pp
AYTU: -23.31% · EOLS: -18.22%
6M Horizon EOLS +15.64 pp
AYTU: -13.81% · EOLS: +1.83%
1Y Horizon EOLS +2.91 pp
AYTU: -12.14% · EOLS: -9.23%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period AYTU Revenue EOLS Revenue AYTU Op. Margin EOLS Op. Margin Margin Leader
FY2019 $10M $30M -230.1% -283.3% AYTU
FY2020 $30M $60M -76.5% -270.7% AYTU
FY2021 $70M $100M -89.7% -44.6% EOLS
FY2022 $100M $150M -113.7% -44.0% EOLS
FY2023 $110M $200M -15.9% -24.4% AYTU
FY2024 $70M $270M -2.4% -12.9% AYTU
FY2025 $70M $300M -11.8% -11.0% EOLS
FY2026 $60M N/A -14.4% N/A AYTU

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AYTU UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AYTU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EOLS CONSOLIDATION
100d in phase · OBV DISTRIBUTION
Current IV 46.4%
IV Percentile 4th %ile
Put/Call OI Skew 0.07x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact EOLS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AYTU Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $19.6M market capitalization and -14.4% operating margin.
OpEx & R&D Reinvestment 78.4% of Rev ($45M)
90D Engineering Disclosures 0 Published
EOLS Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $475.2M market capitalization and -5.4% operating margin.
OpEx & R&D Reinvestment 71.5% of Rev ($233M)
90D Engineering Disclosures 0 Published

Investor FAQ AYTU vs EOLS Key Questions & Quantitative Answers

As of Nov 16, 2026, Evolus, Inc. (EOLS) is the stronger overall head-to-head candidate over AYTU BioPharma, Inc. (AYTU) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). AYTU carries a Unified Composite Score of 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin), whereas EOLS carries 47.8/100 (HOLD) at $6.69 (24.9x Forward P/E, -5.4% operating margin). Composite vs. Pillar Nuance: While AYTU currently prints a higher short-term Unified Composite Score (48.9/100 HOLD vs. EOLS 47.8/100 HOLD), EOLS captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-5.4% vs. -14.4% operating margin) and revenue trajectory (+13.0% vs. +6.4% YoY). Technical & Structure Timing Caution: AYTU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7); meanwhile EOLS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

EOLS leads the Growth & Scale pillar: AYTU posts +6.4% YoY revenue growth and +0.0% YoY earnings growth on $58M TTM revenue (64.0% gross margin, -14.4% operating margin), compared with EOLS at +13.0% YoY revenue growth and +0.0% YoY earnings growth on $325M TTM revenue (66.1% gross margin, -5.4% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), AYTU cumulative revenue shifted +500.0% while EOLS shifted +900.0%. In operating R&D and SG&A reinvestment, AYTU deploys 78.4% of Rev ($45M) (0 90-day corporate R&D disclosures) versus 71.5% of Rev ($233M) (0 disclosures) for EOLS.

AYTU screens cheaper on headline valuation multiples. AYTU trades at 9.2x Forward P/E, 9.2x Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-2.4% FCF margin), whereas EOLS trades at 24.9x Forward P/E, 14.9x Trailing P/E, N/M PEG, and 1.8x EV/Revenue (-2.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AYTU (-52.5% ROE) versus EOLS (-18729.6% ROE) capital efficiency.

In options market volatility and institutional positioning, AYTU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.65β · 35% Vol realized risk). By comparison, EOLS carries 46.4% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.31β · 60% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.